



CIGNA MEDICAL COVERAGE POLICY

The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA.

**Subject Titanium Rib Implants –
Vertical Expandable Prosthetic
Titanium Rib (VEPTR™)**

**Effective Date 12/15/2009
Next Review Date.....12/15/2010
Coverage Policy Number 0259**

Table of Contents

Coverage Policy	1
General Background	1
Coding/Billing Information	3
References	3
Policy History.....	5

Hyperlink to Related Coverage Policies

Diaphragmatic/Phrenic Nerve Stimulation
 Noninvasive Negative Pressure Ventilators
 Percutaneous Vertebroplasty and
 Kyphoplasty
 Scoliosis Treatments, Idiopathic
 Spinal Orthoses
 Surgical Treatment for Chest Wall
 Deformities (Pectus
 Excavatum/Carinatum and Poland
 Syndrome)

INSTRUCTIONS FOR USE

Coverage Policies are intended to provide guidance in interpreting certain **standard** CIGNA HealthCare benefit plans as well as benefit plans formerly administered by Great-West Healthcare. Please note, the terms of a participant's particular benefit plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a participant's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a participant's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable group benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. Proprietary information of CIGNA. Copyright ©2009 CIGNA

Coverage Policy

CIGNA covers the implantation of the Vertical Expandable Prosthetic Titanium Rib (VEPTR™) device as medically necessary when used in accordance with the Humanitarian Device Exemption (HDE) specifications of the U.S. Food and Drug Administration (FDA) for children with thoracic insufficiency syndrome.

CIGNA does not cover the implantation of the VEPTR device for any other indication because it is considered experimental, investigational or unproven.

General Background

Thoracic insufficiency syndrome (TIS) is defined as the inability of the thorax to support normal respiration and lung growth (Campbell, 2004). For children with TIS, treatment is aimed at stabilizing their clinical symptoms while preserving ongoing thoracic spinal growth. Treatment modalities include ventilation support or bracing, implantation of autograft or allograft rib sections, splitting of fused ribs, and insertion of spacers. TIS with progressive scoliosis may be treated by fusing the spine and inserting supportive instrumentation (Schneerson, 2003; Prakash, 2004).

While standard surgical interventions assist in providing spinal support via fusion and/or instrumentation, these interventions do not typically result in added expansion of the anterior chest wall. The Vertical Expandable Prosthetic Titanium Rib (VEPTR™) is an alternative to spinal fusion for children with TIS. Construct options include rib-to-rib, rib to ilium or rib-to-lumber attachment. The latter two construct options include a lumbar extension rod. The device can be lengthened manually to indirectly support the curvature of a young child's spine while allowing the thoracic cavity to expand, thus decreasing restriction of the lungs by the rib cage and spine. During surgery when maximum expansion has been achieved, the VEPTR is locked into position. Depending on the type and severity of the spinal deformity, more than one device may be inserted. The device length is surgically adjusted approximately every four to six months to accommodate for new spinal growth. Complete replacement of the device, to allow for ongoing growth of the child's spine and to maintain maximum support of the chest cavity may be indicated. Once the child reaches skeletal maturity the device may remain in place or may be removed. The advantages of this surgical technique are its indirect treatment of the anatomical causes of TIS, while not interfering with subsequent spinal procedures that may be needed later in life (Synthes, 2009; Freeman, 2003).

U.S. Food and Drug Administration (FDA)

The Vertical Expandable Prosthetic Titanium Rib (VEPTR) (SYNTHES® Spine Co., West Chester, PA) was approved under the FDA Humanitarian Device Exemption (HDE) program in August 2004. The device is indicated for "the treatment of thoracic insufficiency syndrome (TIS) in skeletally immature patients. The FDA stated that for the purpose of identifying potential TIS patients, the categories in which TIS patients often fall include: flail chest syndrome; rib fusion and scoliosis; and hypoplastic thorax syndrome (e.g., Jeune's syndrome, achondroplasia, Jarcho-Levin syndrome and Ellis van Creveld syndrome) (FDA, 2004).

FDA approval was based on a 14-year multicenter study (n=224) conducted by SYNTHES Spine. The children, age six months or older, were divided into four groups by diagnosis: flail chest, rib fusion, hypoplastic thoracic syndrome, and progressive scoliosis. Follow-up visits occurred at 4, 8, 12, 16, 20 and 24 months, and then annually thereafter. Twelve patients died and two withdrew, leaving 210 patients to complete the study. Of the remaining patients, 93.4% showed improved assisted ventilatory rating outcomes. Thoracic dimensions demonstrated that patients with flail chest improved 80%; those with rib fusion improved 91.5%; those with hypoplastic thoracic syndrome improved 84.8%; and those with progressive scoliosis improved 77.4%. The complications, experienced by 119 patients, included: device migration (16%), device failure (2%), spinal abscess (4%), and spinal or surgical site infection (5%) (FDA, 2004).

Specific contraindications to the use of the titanium rib include:

- insufficient bone strength in the ribs or spine where the device would attach
- absence of proximal and distal ribs for attachment of the device
- absence of diaphragmatic function
- insufficient tissue to cover the VEPTR
- age less than six months
- skeletal maturity has been reached (i.e., age 14 for girls and age 16 for boys)
- known allergy to any device materials
- infection near or at the surgical site

Literature Review

Titanium rib implants are an accepted treatment option for children with thoracic insufficiency syndrome. Evidence in the peer-reviewed literature in the form of prospective case series (Campbell, et al., Sep 2007; Emans, et al., 2005; Hell, et al., 2005; Campbell, et al., 2004) and retrospective reviews (Motoyama, et al., 2006; Gollogly, et al., 2004) have reported significant improvements in respiratory function, lung growth and lung volume. Up to 12-year follow-ups have been reported. The number of studies comparing the titanium rib to other treatment modalities is limited.

Other Indications: As a less invasive procedure compared to other surgical interventions (e.g., growing rods), VEPTR has been proposed for the treatment of early-onset scoliosis in children (Ramiz, et al., 2009; Smith, 2007). Smith noted that VEPTR is not FDA approved for children with idiopathic scoliosis without thoracic insufficiency syndrome because it has not clearly been shown to provide benefit. Although acceptable, the

complications of VEPTR are not insignificant. Studies investigating the use of VEPTR for the treatment of scoliosis are primarily in the form of retrospective reviews (Samdani, et al., 2009; Smith, et al., 2009; Ramirez, et al., 2009) and case series (Redding, et al., 2008) with small heterogeneous patient populations (n=10-31) and a mean follow-up of 32 months or less.

Professional Societies/Organizations

Professional society guidelines commenting on the use of the titanium rib for the treatment of thoracic insufficiency syndrome are lacking.

Summary

Vertical Expandable Prosthetic Titanium Rib (VEPTR) is an accepted treatment modality for children with thoracic insufficiency syndrome. While the evidence is not robust, studies in the published peer-reviewed literature have reported that the VEPTR has been successfully used as an alternative to ventilator dependence or spinal fusion. There is insufficient evidence to support the use of VEPTR for any other indication.

Coding/Billing Information

Note: This list of codes may not be all-inclusive.

Covered when medically necessary:

CPT ^{®*} Codes	Description
	No specific codes

HCPCS Codes	Description
	No specific codes

ICD-9-CM Diagnosis Codes	Description
756.3	Other congenital anomaly of ribs and sternum
756.4	Chondrodystrophy,
756.55	Chondroectodermal dysplasia
807.4	Flail chest

*Current Procedural Terminology (CPT[®]) © 2008 American Medical Association: Chicago, IL.

References

1. Campbell RM, Smith MD, Mayes TC, Mangos JA, Willey-Courand DB, Kose N, et al. The effect of opening wedge thoracostomy on thoracic insufficiency syndrome associated with fused ribs and congenital scoliosis. J Bone Joint Surg. 2004 Aug;86:1659-74.
2. Campbell RM Jr, Adcox BM, Smith MD, Simmons JW 3rd, Cofer BR, Inscore SC, Grohman C. The effect of mid-thoracic VEPTR opening wedge thoracostomy on cervical tilt associated with congenital thoracic scoliosis in patients with thoracic insufficiency syndrome. Spine. 2007 Sep 15;32(20):2171-7.
3. Campbell RM Jr, Smith MD. Thoracic insufficiency syndrome and exotic scoliosis. J Bone Joint Surg Am. 2007 Feb;89 Suppl 1:108-22.

4. Emans JB, Caubet JF, Ordonez CL, Lee EY, Ciarlo M. The treatment of spine and chest wall deformities with fused ribs by expansion thoracostomy and insertion of vertical expandable prosthetic titanium rib. *Spine*. 2005;30(17S):S58-68.
5. Freeman BL (author). Chapter 38: Congenital scoliosis. Canale T (editor). In: *Campbell's operative orthopedics*. 10th ed. St. Louis, MO: Mosby, Inc.; 2003.
6. Gollogly S, Smith JT, Campbell RM. Determining lung volume with three-dimensional reconstructions of CT scan data: a pilot study to evaluate the effects of expansion thoracoplasty on children with severe spinal deformities. *J Pediatr Orthop*. 2004 May-Jun;24(3):323-8.
7. Green TP, McColley SA. (authors). Section 3: Disorders of the lungs and lower airways. Behrman RE, Kleigman RM, Jenson HB, (editors). In: *Behrman: Nelson Textbook of Pediatrics*, 17th ed. Philadelphia, PA: W.B. Saunders Company; 2004.
8. Hell AK, Campbell RM, Hefti F. The vertical expandable prosthetic titanium rib implant for the treatment of thoracic insufficiency syndrome associated with congenital and neuromuscular scoliosis in young children. *J Pediatr Orthop B*. 2005 Jul;14(4):287-93.
9. Motoyama EK, Deeney VF, Fine GF, Yang CI, Mutich RL, Walczak SA, Moreland MS. Effects on lung function of multiple expansion throacoplasty in children with thoracic insufficiency syndrome: a longitudinal study. *Spine*. 2006;31(3):284-90.
10. Prakash UB, King TE. (authors). Chapter 62: Skeletal Disorders. In: *Baum's textbook of pulmonary diseases*. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004.
11. Ramirez N, Flynn JM, Serrano JA, Carlo S, Cornier AS. The Vertical Expandable Prosthetic Titanium Rib in the treatment of spinal deformity due to progressive early onset scoliosis. *J Pediatr Orthop B*. 2009 Jul;18(4):197-203.
12. Redding G, Song K, Inscore S, Effmann E, Campbell R. Lung function asymmetry in children with congenital and infantile scoliosis. *Spine J*. 2008 Jul-Aug;8(4):639-44.
13. Samdani AF, Ranade A, Dolch HJ, Williams R, St Hilaire T, Cahill P, Betz RR. Bilateral use of the vertical expandable prosthetic titanium rib attached to the pelvis: a novel treatment for scoliosis in the growing spine. *J Neurosurg Spine*. 2009 Apr;10(4):287-92.
14. Shneerson JM. (author). Chapter 17.13: Disorders of the thoracic cage and diaphragm. In: *Oxford textbook of medicine*. 4th ed. Oxford, UK: Oxford University Press; 2003.
15. Smith JR, Samdani AF, Pahys J, Ranade A, Asghar J, Cahill P, Betz RR. The role of bracing, casting, and vertical expandable prosthetic titanium rib for the treatment of infantile idiopathic scoliosis: a single-institution experience with 31 consecutive patients. *Clinical article. J Neurosurg Spine*. 2009 Jul;11(1):3-8.
16. Smith JT. The use of growth-sparing instrumentation in pediatric spinal deformity. *Orthop Clin North Am*. 2007 Oct;38(4):547-52.
17. SYNTHES® Vertical expandable prosthetic titanium rib. 2009. Accessed Nov 3, 2009. Available at URL address: <http://www.synthes.com/html/VEPTR.7182.0.html>
18. U.S. Food and Drug Administration (FDA): Vertical expandable prosthetic titanium rib (VEPTR). Jun 20, 2009. Accessed Nov 3, 2009. Available at URL address: <http://www.fda.gov/cdrh/MDA/DOCS/h030009.html>
19. U.S. Food and Drug Administration (FDA): Vertical Expandable Prosthetic Titanium Rib (VEPTR) - H030009. Summary of safety and probable benefit. Sep 30, 2004. Accessed Nov 3, 2009. Available at URL address: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=H030009>

Policy History

Pre-Merger Organizations	Last Review Date	Policy Number	Title
CIGNA HealthCare	12/15/2007	0259	Titanium Rib Implants – Vertical Expandable Prosthetic Titanium Rib (VEPTR)
Great-West Healthcare	10/26/2006	04.261.02	Titanium Rib Implant

“CIGNA” and the “Tree of Life” logo are registered service marks of CIGNA Intellectual Property, Inc., licensed for use by CIGNA Corporation and its operating subsidiaries. All products and services are provided exclusively by such operating subsidiaries and not by CIGNA Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, CIGNA Behavioral Health, Inc., Intracorp, and HMO or service company subsidiaries of CIGNA Health Corporation and CIGNA Dental Health, Inc. In Arizona, HMO plans are offered by CIGNA HealthCare of Arizona, Inc. In California, HMO plans are offered by CIGNA HealthCare of California, Inc. and Great-West Healthcare of California, Inc. In Connecticut, HMO plans are offered by CIGNA HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by CIGNA HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by CIGNA HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company.

Connecticut General Life Insurance Company has acquired the business of Great-West Healthcare from Great-West Life & Annuity Insurance Company (GWLA). Certain products continue to be provided by GWLA (Life, Accident and Disability, and Excess Loss). GWLA is not licensed to do business in New York. In New York, these products are sold by GWLA's subsidiary, First Great-West Life & Annuity Insurance Company, White Plains, N.Y.